

# Ute Katharina Bartels

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8192352/publications.pdf>

Version: 2024-02-01

177  
papers

7,590  
citations

101543

36  
h-index

58581

82  
g-index

180  
all docs

180  
docs citations

180  
times ranked

8153  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
2	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. <i>Acta Neuropathologica</i> , 2012, 124, 439-447.	7.7	799
3	Diffuse brainstem glioma in children: critical review of clinical trials. <i>Lancet Oncology</i> , The, 2006, 7, 241-248.	10.7	547
4	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. <i>Nature Genetics</i> , 2014, 46, 451-456.	21.4	525
5	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
6	Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. <i>Acta Neuropathologica</i> , 2014, 128, 573-581.	7.7	258
7	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	1.6	250
8	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. <i>Cancer Cell</i> , 2020, 37, 569-583.e5.	16.8	244
9	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	1.6	232
10	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	12.8	200
11	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	16.8	191
12	Consensus on the management of intracranial germ-cell tumours. <i>Lancet Oncology</i> , The, 2015, 16, e470-e477.	10.7	173
13	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
14	Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3537-3543.	1.6	157
15	Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. <i>Neuro-Oncology</i> , 2016, 18, 291-297.	1.2	112
16	Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. <i>Nature Genetics</i> , 2015, 47, 263-266.	21.4	109
17	Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. <i>Cancer</i> , 2016, 122, 1261-1269.	4.1	109
18	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	1.6	106

#	ARTICLE	IF	CITATIONS
19	Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. <i>Acta Neuropathologica Communications</i> , 2016, 4, 93.	5.2	100
20	Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. <i>Neuro-Oncology</i> , 2017, 19, 1279-1280.	1.2	93
21	Limited-field radiation for bifocal germinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 486-492.	0.8	86
22	Intracystic Therapies for Cystic Craniopharyngioma in Childhood. <i>Frontiers in Endocrinology</i> , 2012, 3, 39.	3.5	86
23	Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3283-3290.	1.6	78
24	Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training. <i>Neuro-Oncology</i> , 2017, 19, now177.	1.2	73
25	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4161-4170.	1.6	72
26	Basal ganglia germinoma in children with associated ipsilateral cerebral and brain stem hemiatrophy. <i>Pediatric Radiology</i> , 2006, 36, 325-330.	2.0	70
27	Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation. <i>Journal of Neuro-Oncology</i> , 2016, 127, 173-180.	2.9	64
28	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. <i>JCO Precision Oncology</i> , 2020, 4, 561-571.	3.0	62
29	EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. <i>Neuro-Oncology</i> , 2022, 24, 516-527.	1.2	60
30	Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. <i>Lancet Oncology</i> , The, 2016, 17, e163-e172.	10.7	56
31	Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances. <i>Journal of Neuro-Oncology</i> , 2011, 101, 75-81.	2.9	52
32	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26988.	1.5	51
33	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. <i>Neuro-Oncology</i> , 2020, 22, 1647-1657.	1.2	51
34	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. <i>Cancer</i> , 2019, 125, 1867-1876.	4.1	49
35	Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2014, 16, 1554-1559.	1.2	44
36	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40

#	ARTICLE	IF	CITATIONS
37	Long-term visual outcomes of craniopharyngioma in children. Journal of Neuro-Oncology, 2018, 137, 645-651.	2.9	39
38	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.	1.2	39
39	Intracranial Germ Cell Tumors in Adolescents and Young Adults: A 40-Year Multi-Institutional Review of Outcomes. International Journal of Radiation Oncology Biology Physics, 2020, 106, 269-278.	0.8	38
40	Concordance between the change and the International Society of Pediatric Oncology (<sc>SIOP</sc>) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 601-605.	1.5	36
41	Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy. Journal of Neuro-Oncology, 2010, 97, 393-399.	2.9	34
42	Favorable outcome with conservative treatment for children with low grade brainstem tumors. Pediatric Blood and Cancer, 2012, 58, 556-560.	1.5	33
43	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. Neuro-Oncology, 2019, 21, 547-557.	1.2	32
44	Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. Journal of Neurosurgery: Pediatrics, 2006, 104, 314-320.	1.3	30
45	Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study. Neuro-Oncology, 2022, 24, 974-983.	1.2	30
46	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. Journal of Neuro-Oncology, 2017, 132, 323-331.	2.9	27
47	Inherent diagnostic and treatment challenges in germinoma of the basal ganglia: a case report and review of the literature. Journal of Neuro-Oncology, 2008, 88, 309-314.	2.9	26
48	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
49	Role of spinal MRI in the follow-up of children treated for medulloblastoma. Cancer, 2006, 107, 1340-1347.	4.1	23
50	Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. Journal of Neuro-Oncology, 2020, 147, 721-730.	2.9	21
51	Challenges Faced by Pediatric Oncology Fellows When Patients Die During Their Training. Journal of Oncology Practice, 2015, 11, e182-e189.	2.5	19
52	Determinants of quality of life outcomes for survivors of pediatric brain tumors. Pediatric Blood and Cancer, 2017, 64, e26481.	1.5	18
53	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. Journal of Neuro-Oncology, 2019, 145, 107-114.	2.9	18
54	Predictors of Symptoms and Site of Death in Pediatric Palliative Patients With Cancer at End of Life. American Journal of Hospice and Palliative Medicine, 2014, 31, 548-552.	1.4	17

#	ARTICLE	IF	CITATIONS
55	Targeted Therapy in Pediatric Low-Grade Glioma. Current Neurology and Neuroscience Reports, 2014, 14, 441.	4.2	16
56	Dose-level response rates of mTOR inhibition in tuberous sclerosis complex related subependymal giant cell astrocytoma. Pediatric Blood and Cancer, 2015, 62, 1754-1760.	1.5	16
57	Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. Lancet Oncology, The, 2018, 19, e419-e428.	10.7	16
58	Are we friends? Best friend nominations in pediatric brain tumor survivors and associated factors. Supportive Care in Cancer, 2019, 27, 4237-4244.	2.2	16
59	When a child dies: pediatric oncologists' follow-up practices with families after the death of their child. Psycho-Oncology, 2015, 24, 1626-1631.	2.3	15
60	Predicting social withdrawal, anxiety and depression symptoms in pediatric brain tumor survivors. Journal of Psychosocial Oncology, 2019, 37, 22-36.	1.2	15
61	Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines. Lancet Oncology, The, 2020, 21, e444-e451.	10.7	15
62	Bridging the Distance in the Caribbean: Telemedicine as a means to build capacity for care in paediatric cancer and blood disorders. Studies in Health Technology and Informatics, 2015, 209, 1-8.	0.3	15
63	Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. International Journal of Radiation Oncology Biology Physics, 2015, 93, 47-53.	0.8	14
64	Review of management and morbidity of pediatric craniopharyngioma patients in a low-middle-income country: a 12-year experience. Child's Nervous System, 2017, 33, 941-950.	1.1	14
65	Video-Teleconferencing in Pediatric Neuro-Oncology: Ten Years of Experience. Journal of Global Oncology, 2018, 4, 1-7.	0.5	14
66	Repeat irradiation for children with supratentorial high-grade glioma. Pediatric Blood and Cancer, 2019, 66, e27881.	1.5	14
67	Long term toxicity of intracranial germ cell tumor treatment in adolescents and young adults. Journal of Neuro-Oncology, 2020, 149, 523-532.	2.9	14
68	Determinants of social competence in pediatric brain tumor survivors who participated in an intervention study. Supportive Care in Cancer, 2017, 25, 2891-2898.	2.2	13
69	The Latin American Brain Tumor Board teleconference: results of a web-based survey to evaluate participant experience utilizing this resource. Child's Nervous System, 2019, 35, 257-265.	1.1	13
70	Executive functions and social skills in pediatric brain tumor survivors. Applied Neuropsychology: Child, 2020, 9, 83-91.	1.4	13
71	Canadian Pediatric Neuro-Oncology Standards of Practice. Frontiers in Oncology, 2020, 10, 593192.	2.8	13
72	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. Acta Neuropathologica Communications, 2018, 6, 67.	5.2	12

#	ARTICLE	IF	CITATIONS
73	Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. <i>Neuro-Oncology</i> , 2020, 22, 1873-1881.	1.2	12
74	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 800-813.	5.6	12
75	Symptom interval and treatment burden for patients with malignant central nervous system germ cell tumours. <i>Archives of Disease in Childhood</i> , 2020, 105, 247-252.	1.9	12
76	Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 1950-1961.	1.2	12
77	Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children. <i>Journal of Clinical Oncology</i> , 2021, 39, 3813-3821.	1.6	11
78	Assessment of chemotherapeutic response in children with proptosis due to optic nerve glioma. <i>Child's Nervous System</i> , 2008, 24, 707-712.	1.1	10
79	Causes of death in pediatric neuro-oncology: the sickkids experience from 2000 to 2017. <i>Journal of Neuro-Oncology</i> , 2020, 149, 181-189.	2.9	10
80	The clinical significance of equivocal findings on spinal MRI in children with medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26472.	1.5	9
81	Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review. <i>Child's Nervous System</i> , 2019, 35, 861-864.	1.1	9
82	Bevacizumab for pediatric radiation necrosis. <i>Neuro-Oncology Practice</i> , 2020, 7, 409-414.	1.6	9
83	Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	1.2	9
84	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. <i>Neuro-Oncology</i> , 2022, 24, 821-833.	1.2	9
85	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). <i>Journal of Neuro-Oncology</i> , 2020, 149, 45-54.	2.9	8
86	SIOP PODCâ€“adapted treatment guidelines for craniopharyngioma in lowâ€•and middleâ€•income settings. <i>Pediatric Blood and Cancer</i> , 2023, 70, e28493.	1.5	8
87	The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). <i>Journal of Neuro-Oncology</i> , 2020, 147, 731-736.	2.9	8
88	Hearing loss and intellectual outcome in children treated for embryonal brain tumors: Implications for young children treated with radiation sparing approaches. <i>Cancer Medicine</i> , 2021, 10, 7111-7125.	2.8	8
89	GC-17THE CHILDREN'S ONCOLOGY GROUP (COG) CURRENT TREATMENT APPROACH FOR CHILDREN WITH NEWLY DIAGNOSED CENTRAL NERVOUS SYSTEM (CNS) LOCALIZED GERMINOMA (ACNS1123 STRATUM 2). <i>Neuro-Oncology</i> , 2016, 18, iii45.4-iii46.	1.2	7
90	Redefining Ventricular Target Volume in Germinoma: Is Inclusion of Temporal Horns Necessary?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 852-858.	0.8	7

#	ARTICLE	IF	CITATIONS
91	Follow-up evaluation of a web-based pediatric brain tumor board in Latin America. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29073.	1.5	7
92	A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 143-151.	0.8	7
93	Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. <i>Pediatric Neurology</i> , 2015, 53, 238-242.e1.	2.1	6
94	Family environment as a predictor and moderator of cognitive and psychosocial outcomes in children treated for posterior fossa tumors. <i>Child Neuropsychology</i> , 2021, 27, 641-660.	1.3	6
95	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. <i>Journal of Neuro-Oncology</i> , 2021, 155, 63-70.	2.9	6
96	Radiomic Features Based on MRI Predict Progression-Free Survival in Pediatric Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma. <i>Canadian Association of Radiologists Journal</i> , 2023, 74, 119-126.	2.0	6
97	End-of-life care of children with diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 147-153.	2.9	5
98	A Novel Approach to Understanding Social Behaviors in Pediatric Brain Tumor Survivors: A Pilot Study. <i>Journal of Pediatric Psychology</i> , 2021, 46, 80-90.	2.1	5
99	GCT-41. RESPONSE-BASED RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED CENTRAL NERVOUS SYSTEM LOCALIZED GERMINOMA: A CHILDREN'S ONCOLOGY GROUP (COG) PROSPECTIVE PHASE 2 CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii336-iii336.	1.2	5
100	Intracystic interferon-alpha in pediatric craniopharyngioma patients-reply. <i>Neuro-Oncology</i> , 2017, 19, 1420-1421.	1.2	4
101	DEV-14. IMPACT OF A LATIN AMERICA-WIDE TELECONFERENCED BRAIN TUMOR BOARD. <i>Neuro-Oncology</i> , 2018, 20, i47-i48.	1.2	4
102	GERM-15. A PHASE 2 TRIAL OF RESPONSE-BASED RADIATION THERAPY FOR PATIENTS WITH LOCALIZED CENTRAL NERVOUS SYSTEM GERM CELL TUMORS (CNS GCT): A CHILDREN'S ONCOLOGY GROUP (COG) STUDY. <i>Neuro-Oncology</i> , 2018, 20, i86-i86.	1.2	4
103	Indolent course of brainstem tumors with K27M H3.3 mutation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28102.	1.5	4
104	Building the ecosystem for pediatric neuro-oncology care in Pakistan: Results of a 7-year long twinning program between Canada and Pakistan. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29726.	1.5	4
105	Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group. <i>Lancet Oncology</i> , The, 2022, 23, e218-e228.	10.7	4
106	Characteristics of children >36 months of age with DIPG: A report from the international DIPG registry. <i>Neuro-Oncology</i> , 2022, 24, 2190-2199.	1.2	4
107	Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1. <i>Frontiers in Surgery</i> , 2022, 9, 886697.	1.4	4
108	Diagnostic discrepancies between antemortem clinical diagnosis and autopsy findings in pediatric cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1179-1185.	2.8	3



#	ARTICLE	IF	CITATIONS
109	Evaluation of the Pediatric Neuro-Oncology Resources Available in Chile. JCO Global Oncology, 2021, 7, 425-434.	1.8	3
110	Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. Pediatric Blood and Cancer, 2021, 68, e29172.	1.5	3
111	Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?. Neuro-Oncology, 2021, 23, 1627-1628.	1.2	3
112	Ventricular size determination and management of ventriculomegaly and hydrocephalus in patients with diffuse intrinsic pontine glioma: an institutional experience. Journal of Neurosurgery, 2021, 135, 1139-1145.	1.6	3
113	Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.. Journal of Clinical Oncology, 2016, 34, 10509-10509.	1.6	3
114	Prognostic factors related to overall survival in adolescent and young adults with medulloblastoma: a systematic review. Neuro-Oncology Advances, 0, , .	0.7	3
115	Impact of home-based cognitive or academic intervention on working memory and mathematics outcomes in pediatric brain tumor survivors: the Keys to Succeed pilot randomized controlled clinical trial. Child Neuropsychology, 2022, 28, 1116-1140.	1.3	3
116	IMMU-08. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: efficacy, safety, biomarker, and pharmacokinetic results from Checkmate 908. Neuro-Oncology, 2022, 24, i82-i83.	1.2	3
117	Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series. Pediatric Blood and Cancer, 2020, 67, e28690.	1.5	2
118	Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma. Pediatric Blood and Cancer, 2021, 68, e28561.	1.5	2
119	Long-term medical imaging use in children with central nervous system tumors. PLoS ONE, 2021, 16, e0248643.	2.5	2
120	Weekly vinblastine in chemotherapy-naïve children with unresectable or progressive low grade glioma: A Canadian cooperative study.. Journal of Clinical Oncology, 2013, 31, 10029-10029.	1.6	2
121	Pediatric Brain Tumor Survivors'™ Understanding of Friendships: A Qualitative Analysis of ADOS-2 Interview Responses. Journal of Pediatric Psychology, 2022, , .	2.1	2
122	Successful management of symptomatic hydrocephalus using a temporary external ventricular drain with or without endoscopic third ventriculostomy in pediatric patients with germinoma. Journal of Neurosurgery, 2021, , 1-6.	1.6	2
123	GCT-22. OUTCOMES OF CHILDREN WITH LOCALIZED AND METASTATIC GERMINOMA TREATED WITH CHEMOTHERAPY FOLLOWED BY RADIATION THERAPY WITHOUT PRIMARY TUMOR BOOST. Neuro-Oncology, 2022, 24, i59-i59.	1.2	2
124	RTHP-34. CRANIOSPINAL IRRADIATION (CSI) AS PART OF RE-IRRADIATION (RT2) FOR CHILDREN WITH RECURRENT INTRACRANIAL EPENDYMOMA. Neuro-Oncology, 2018, 20, vi232-vi232.	1.2	1
125	LGG-60. THE GENETIC LANDSCAPE OF PEDIATRIC LOW-GRADE GLIOMAS: INCIDENCE, PROGNOSIS AND RESPONSE TO THERAPY. Neuro-Oncology, 2018, 20, i117-i117.	1.2	1
126	DIPG-69. CHARACTERISTICS OF PATIENTS ≥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2018, 20, i63-i63.	1.2	1



#	ARTICLE	IF	CITATIONS
127	DEV-07. THE LATIN-AMERICAN BRAIN TUMOR BOARD (LATB) TELECONFERENCE: RESULTS OF A WEB-BASED SURVEY TO EVALUATE PARTICIPANT EXPERIENCE AND THE PROGRAM. <i>Neuro-Oncology</i> , 2018, 20, i46-i46.	1.2	1
128	“Not all that glitters is gold” insights from the Far East and how to solve a conundrum. <i>Neuro-Oncology</i> , 2019, 21, 1490-1492.	1.2	1
129	Early signs of metabolic syndrome in pediatric central nervous system tumor survivors after high-dose chemotherapy and autologous stem-cell transplantation and radiation. <i>Child's Nervous System</i> , 2021, 37, 1087-1094.	1.1	1
130	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2019-2019.	1.6	1
131	Re-irradiation for relapsed paediatric ependymoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10565-10565.	1.6	1
132	QOL-09. WHOLE-BRAIN WHITE MATTER NETWORK CONNECTIVITY IS DISRUPTED BY PEDIATRIC BRAIN TUMOR TREATMENT. <i>Neuro-Oncology</i> , 2020, 22, iii432-iii432.	1.2	1
133	GCT-18. Endoscopic third ventriculostomy (ETV) and tumor biopsy are not associated with relapse rate or patterns in primary central nervous system (CNS) germ cell tumor (GCT). <i>Neuro-Oncology</i> , 2022, 24, i58-i58.	1.2	1
134	DETAILED MOLECULAR CHARACTERISATION OF DIFFUSE INTRINSIC PONTINE GLIOMAS IDENTIFIES THREE MOLECULAR SUBGROUPS AND A NOVEL CANCER DRIVER, ACVR1. <i>Neuro-Oncology</i> , 2014, 16, iii26-iii27.	1.2	0
135	RA-10SUBTLE FINDINGS ON SPINAL MRIs IN CHILDREN NEWLY DIAGNOSED WITH MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, iii166.5-iii167.	1.2	0
136	CMS-03RISK FACTORS FOR LONG TERM SPEECH DEFICITS IN CHILDREN WITH CEREBELLAR MUTISM SYNDROME. <i>Neuro-Oncology</i> , 2016, 18, iii16.3-iii16.	1.2	0
137	CMS-09BEHAVIOR AND TEMPERAMENT IN CHILDREN TREATED FOR PEDIATRIC MEDULLOBLASTOMA WITH POSTOPERATIVE CEREBELLAR MUTISM SYNDROME. <i>Neuro-Oncology</i> , 2016, 18, iii17.4-iii17.	1.2	0
138	GERM-23. INTRACRANIAL GROWING TERATOMA SYNDROME (IGTS): AN INTERNATIONAL RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , 2018, 20, i88-i88.	1.2	0
139	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, i106-i106.	1.2	0
140	EPEN-31. SUBGROUP SPECIFIC LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOMES IN POSTERIOR FOSSA EPENDYMOMA (PFE). <i>Neuro-Oncology</i> , 2018, 20, i79-i79.	1.2	0
141	GERM-08. EARLIER RECOGNITION OF SYMPTOMS AND DIAGNOSIS MAY REDUCE TREATMENT AND LATE EFFECT BURDEN IN CHILDREN, TEENAGERS AND YOUNG ADULTS WITH INTRACRANIAL GERM CELL TUMOURS. <i>Neuro-Oncology</i> , 2018, 20, i84-i85.	1.2	0
142	TBIO-30. MOLECULAR LANDSCAPE AND CLINICAL CORRELATIONS OF CNS SARCOMAS. <i>Neuro-Oncology</i> , 2018, 20, i186-i186.	1.2	0
143	DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i53-i53.	1.2	0
144	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	1.2	0

#	ARTICLE	IF	CITATIONS
145	DIPG-70. CLINICAL, RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN <3 YEARS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2018, 20, i63-i63.	1.2	0
146	LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FORM THE INTERNATIONAL PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii100-ii100.	1.2	0
147	DIPG-36. CLINICAL, RADIOLOGICAL, AND HISTO-MOLECULAR CHARACTERISTICS OF DIFFUSE INTRINSIC PONTINE GLIOMA IN PATIENTS WHO SURVIVE LESS THAN 3 MONTHS FROM DIAGNOSIS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2019, 21, ii76-ii77.	1.2	0
148	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii102-ii102.	1.2	0
149	In Reply to Byun etÂal. International Journal of Radiation Oncology Biology Physics, 2020, 106, 219-220.	0.8	0
150	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. Neuro-Oncology, 2020, 22, iii327-iii328.	1.2	0
151	Imaging of metastatic medulloblastoma in the molecular era.. Journal of Clinical Oncology, 2016, 34, e22003-e22003.	1.6	0
152	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.. Journal of Clinical Oncology, 2017, 35, 10503-10503.	1.6	0
153	Neurocognitive outcome in children with sensorineural hearing loss after treatment of malignant embryonal brain tumors.. Journal of Clinical Oncology, 2017, 35, 2029-2029.	1.6	0
154	The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pool analysis of cooperative group clinical trials.. Journal of Clinical Oncology, 2020, 38, 2503-2503.	1.6	0
155	DIPG-20. DETERMINATION AND MANAGEMENT OF HYDROCEPHALUS IN PATIENTS WITH DIPG, AN INSTITUTIONAL EXPERIENCE. Neuro-Oncology, 2020, 22, iii291-iii291.	1.2	0
156	GCT-33. A PHASE 2 TRIAL OF RESPONSE-BASED RADIATION THERAPY FOR PATIENTS WITH LOCALIZED CENTRAL NERVOUS SYSTEM GERM CELL TUMORS: A CHILDRENâ€™S ONCOLOGY GROUP (COG) STUDY. IMPACT OF RAPID CENTRAL RADIOTHERAPY REVIEW ON RADIOTHERAPY QUALITY AND PATTERN OF FAILURE FOR NON-GERMINOMATOUS GERM CELL TUMORS. Neuro-Oncology, 2020, 22, iii334-iii334.	1.2	0
157	GCT-21. CENTRAL NERVOUS SYSTEM GERMINOMA - PONDERING THE NEXT STEPS. Neuro-Oncology, 2020, 22, iii332-iii332.	1.2	0
158	DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2020, 22, iii301-iii302.	1.2	0
159	DIPG-55. PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2020, 22, iii297-iii298.	1.2	0
160	LINC-21. SURVEY ON THE RESOURCES AVAILABLE FOR PEDIATRIC NEURO-ONCOLOGY IN CHILE, SOUTH AMERICA. Neuro-Oncology, 2020, 22, iii382-iii382.	1.2	0
161	MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY. Neuro-Oncology, 2020, 22, iii394-iii394.	1.2	0
162	LINC-18. FOLLOW-UP EVALUATION OF A WEB-BASED PEDIATRIC BRAIN TUMOR BOARD IN LATIN AMERICA. Neuro-Oncology, 2020, 22, iii381-iii382.	1.2	0

#	ARTICLE	IF	CITATIONS
163	DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. Neuro-Oncology, 2020, 22, iii295-iii296.	1.2	0
164	LINC-10. SIOP PODC ADAPTED TREATMENT GUIDELINES FOR CRANIOPHARYNGIOMA IN LOW- AND MIDDLE-INCOME SETTINGS. Neuro-Oncology, 2020, 22, iii379-iii380.	1.2	0
165	GCT-42. CLINICAL CHARACTERISTICS OF LOCALIZED CENTRAL NERVOUS SYSTEM NON-GERMINOMATOUS GERM CELL TUMORS (NGGCT) PATIENTS ENROLLED ON ACNS1123 WITH RELAPSE: A CHILDRENâ€™S ONCOLOGY GROUP (COG) STUDY. Neuro-Oncology, 2020, 22, iii336-iii336.	1.2	0
166	RARE-09. PRESERVATION OF ENDOCRINE FUNCTION AFTER OMMAYA RESERVOIR INSERTION IN CHILDREN WITH CYSTIC CRANIOPHARYNGIOMA. Neuro-Oncology, 2020, 22, iii443-iii443.	1.2	0
167	GCT-75. ISOLATED PITUITARY STALK THICKENING. Neuro-Oncology, 2020, 22, iii343-iii343.	1.2	0
168	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. Neuro-Oncology, 2020, 22, iii377-iii377.	1.2	0
169	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. Neuro-Oncology, 2020, 22, iii332-iii332.	1.2	0
170	NIMG-31. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. Neuro-Oncology, 2020, 22, ii154-ii154.	1.2	0
171	EPID-26. CLINICAL AND HISTOLOGICAL CHARACTERIZATION OF PRIMARY CENTRAL NERVOUS SYSTEM SARCOMA IN PEDIATRICS. A SINGLE INSTITUTION EXPERIENCE IN A MIDDLE-INCOME COUNTRY. Neuro-Oncology, 2020, 22, ii84-ii84.	1.2	0
172	GCT-04. Pattern of Treatment Failures in Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT): A Pooled Analysis of Clinical Trials. Neuro-Oncology, 2022, 24, i54-i54.	1.2	0
173	SURG-12. Endoscopic evaluation of ventricular dissemination in primary central nervous system (CNS) germ cell tumors (GCTs). Neuro-Oncology, 2022, 24, i144-i144.	1.2	0
174	GCT-02. Imaging response assessment for Central Nervous System Germ Cell Tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group (SIOPE-BTG) and North American Childrenâ€™s Oncology Group (COG). Neuro-Oncology, 2022, 24, i53-i54.	1.2	0
175	IMG-08. Response assessment for pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Neuro-Oncology, 2022, 24, i78-i78.	1.2	0
176	GCT-05. Multi-institutional analysis of treatment modalities in metastatic germinoma in children. Neuro-Oncology, 2022, 24, i54-i55.	1.2	0
177	LINC-22. Primary central nervous system (CNS) germ cell tumors (GCT) in Central America and the Caribbean region: an AHOPCA 20-year experience. Neuro-Oncology, 2022, 24, i167-i167.	1.2	0